Systemic interleukin-6 responses following administration of adenovirus gene transfer vectors to humans by different routes

Molecular Therapy

Volumn 6, Issue 2, 2002, Pages 287-297

  Harvey, Ben Gary ^a   McKinney, Robin L ^a   Rosengart, Todd ^b   Lesser, Martin L ^c   Crystal, Ronald G ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b EVANSTON NORTHWESTERN HEALTHCARE   (United States)

^c Center for Neurosciences   (United States)

Author keywords

Ad vectors; Anti Ad neutralizing metabolism; Gene therapy; Human; IL 6; Innate responses

Indexed keywords

ADENOVIRUS VECTOR; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; COMPLEMENTARY DNA; CYTOSINE DEAMINASE; FLUCYTOSINE; INTERLEUKIN 6; NEUTRALIZING ANTIBODY; TRANSMEMBRANE CONDUCTANCE REGULATOR; VASCULOTROPIN;

AIRWAY; BRONCHOSCOPY; CLINICAL TRIAL; COLON CARCINOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CYSTIC FIBROSIS; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART MUSCLE; HUMAN; IMMUNE RESPONSE; LEG MUSCLE; LIVER METASTASIS; MALE; META ANALYSIS; PERIPHERAL VASCULAR DISEASE; REVIEW; SKIN; THORAX SURGERY; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ANIMALIA; ESCHERICHIA COLI;

EID: 0036664450     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1006/mthe.2002.0658     Document Type: Review

References (48)

1. Crystal, R. G. (1995). Transfer of genes to humans: early lessons and obstacles to success. Science 270: 404-410.
2. Wilson, J. M. (1996). Adenoviruses as gene-delivery vehicles. N. Engl J. Med. 334: 1185-1187.
3. Anderson, W. F. (1998). Human gene therapy. Nature 392: 25-30.
4. Yang, Y., Li, Q., Ertl, H. C., and Wilson, J. M. (1995). Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J. Virol. 69: 2004-2015.
5. Yang, Y., Jooss, K. U., Su, Q., Ertl, H. C., and Wilson, J. M. (1996). Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. Gene Ther. 3: 137-144.
6. O'Neal, W. K., et al. (1998). Toxicological comparison of E2a-deleted and first-generation adenoviral vectors expressing α1-antitrypsin after systemic delivery. Hum. Gene Ther. 9: 1587-1598.
7. Brody, S. L., Metzger, M., Danel, C., Rosenfeld, M. A., and Crystal, R. G. (1994). Acute responses of non-human primates to airway delivery of an adenovirus vector containing the human cystic fibrosis transmembrane conductance regulator cDNA. Hum. Gene Ther. 5: 821-836.
8. Kaplan, J. M., et al. (1997). Characterization of factors involved in modulating persistence of transgene expression from recombinant adenovirus in the mouse lung. Hum. Gene Ther. 8: 45-56.
9. Wolff, G., Worgall, S., van Rooijen, N., Song, W. R., Harvey, B. G., and Crystal, R. G. (1997). Enhancement of in vivo adenovirus-mediated gene transfer and expression by prior depletion of tissue macrophages in the target organ. J. Virol. 71: 624-629.
10. Worgall, S., Leopold, P. L., Wolff, G., Ferris, B., van Roijen, N., and Crystal, R. G. (1997). Role of alveolar macrophages in rapid elimination of adenovirus vectors administered to the epithelial surface of the respiratory tract. Hum. Gene Ther. 8: 1675-1684
11. Lieber, A., He, C. Y., Meuse, L., Himeda, C., Wilson, C., and Kay, M. A. (1998). Inhibition of NF-κB activation in combination with bcl-2 expression allows for persistence of first-generation adenovirus vectors in the mouse liver. J. Virol. 72: 9267-9277.
12. Otake, K., Ennist, D. L., Harrod, K., and Trapnell, B. C. (1998). Nonspecific inflammation inhibits adenovirus-mediated pulmonary gene transfer and expression independent of specific acquired immune responses. Hum. Gene Ther. 9: 2207-2222.
13. Lozier, J. N., Metzger, M. E., Donahue, R. E., and Morgan, R. A. (1999). Adenovinus-mediated expression of human coagulation factor IX in the rhesus macaque is associated with dose-limiting toxicity. Blood 94: 3968-3975.
14. Muruve, D. A., Barnes, M. J., Stillman, I. E., and Libermann, T. A. (1999). Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo. Hum. Gene Ther. 10: 965-976.
15. Peng, Y., et al. (1999). Inhibition of tumor necrosis factor α by an adenovirus-encoded soluble fusion protein extends transgene expression in the liver and lung. J. Virol 73: 5098-5109.
16. Driesse, M. J., et al. (2000). Intra-CSF administered recombinant adenovirus causes an immune response-mediated toxicity. Gene Ther. 7: 1401-1409.
17. Minter, R. M., et al. (2000). TNF-α receptor signaling and IL-10 gene therapy regulate the innate and humoral immune responses to recombinant adenovirus in the lung. J. Immunol. 164: 443-451.
18. Schnell, M. A., et al. (2001). Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors. Mol. Ther. 3: 708-722, doi.10.1006/mthe.2001.0030.
19. Zhang, Y., et al. (2001). Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages. Mol. Ther. 3: 697-707, doi.10.1006/mthe.2001.0329.
20. Zitnik, R. J., and Elias, J. A. (1993): Interleukin-6 and the lung. In Cytokine of the lung (J. Kelley, Ed.), pp. 229-279. Marcel Dekker Inc., New York.
21. Crystal, R. G., et al. (1994). Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nat. Genet. 8: 42-51.
22. McElvaney, N. G., and Crystal, R. G. (1995). IL-6 release and airway administration of human CFR cDNA adenovirus vector. Nat. Med. 1: 182-184.
23. Cox, G., and Gauldie, J. (1997). Interleukin-6, In, Cytokines in Health (D. G. Remick, et al., Eds.) pp. 81-99. Marcel Dekker Inc., New York.
24. Benihoud, K., et al. (2000). The role of IL-6 in the inflammatory and humoral response to adenoviral vectors. J. Gene Med. 2: 194-203.
25. Eriksson-Mjoberg, M., Kristiansson, M., Carlstrom, K., Olund, A., and Eklund, J. (1997). Infiltration of morphine into an abnormal wound; effects on pain relief and endocrine/immune response. Pain 73: 355-360.
26. Krause, A., Hohberg, B., Heine, F., John, M., Burmester, G. R., and Witt, C. (1997). Cytokines derived from alveolar macrophages induce fever after bronchoscopy and bronchoalveolar lavage. Am. J. Respir. Crit. Care Med. 155: 1793-1797.
27. Czerny, M., et al. (2000). Inflammatory response and myocardial injury following coronary artery bypass grafting with or without cardiopulmonary bypass. Eur. J. Cardiothorac. Surg. 17: 737-742.
28. Sugi, K., Kaneda, Y., and Esato, K. (2000). Video-assisted thoracoscopic lobectomy reduces cytokine production more than conventional open lobectomy. Jpn. J. Thoroc. Cardiovasc. Surg. 48: 161-165.
29. Yim, A. P., Wan, S., Lee, T. W., and Arifi, A. A. (2000). VATS lobectomy reduces cytokine responses compared with conventional surgery. Ann. Thorac. Surg. 70: 243-247.
30. Terashima, T., Amakawa, K., Matsumaru, A., van Eeden, S., Hogg, J. C., and Yamaguchi, K. (2001). BAL induces an increase in peripheral blood neutrophils and cytokine levels in healthy volunteers and patients with pneumonia. Chest 119: 1724-1729.
31. Kopf, M., Herren, S., Wiles, M. V., Pepys, M. B., and Kosco-Vilbois, M. H. (1998). Interleulkin 6 influences germinal center development and antibody production via a contribution of C3 complement component. J. Exp. Med. 188: 1895-1906.
32. Xing, Z., Braciak, T., Chong, D., Feng, X., Schroeder, J. A., and Gauldie, J. (1999). Adenoviral-mediated gene transfer of interleukin-6 in rat lung enhances antiviral immunoglobulin A and G responses in distinct tissue compartments. Biochem. Biophys. Res. Commun. 258: 332-335.
33. Zsengeller, Z., Otake, K., Hossain, S. A., Berclaz, P. Y., and Trapnell, B. C. (2000). Internalization of adenovirus by alveolar macrophages initiates early proinflarnmatory signaling during acute respiratory tract infection. J. Virol. 74: 9655-9667.
34. Knowles, M. R., et al. (1995). A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis. N. Engl. J. Med. 333: 823-831.
35. Zabner, J., et al. (1996). Repeat administration of an adenovirus vector encoding cystic fibrosis transmembrane conductance regulator to the nasal epithelium of patients with cystic fibrosis. J. Clin. Invest. 97: 1504-1511.
36. Bellon, G., et al. (1997). Aerosol administration of a recombinant adenovirus expressing CFTR to cystic fibrosis patients: a phase I clinical trial. Hum. Gene Ther. 8: 15-25.
37. Joseph, P. M., et al. (2001). Aerosol and lobar administration of a recombinant adenovirus to individuals with cystic fibrosis. I. methods, safety, and clinical implications. Hum. Gene Ther. 12: 1369-1382.
38. Crystal, R. G., et al. (1997). Phase I study of direct administration of a replication deficient adenovirus vector containing the E. coli cytosine deaminase gene to metastatic colon carcinoma of the liver in association with the oral administration of the pro-drug 5-fluorocytosine. Hum. Gene Ther. 8: 985-1001.
39. Rosengart, T. K., et al. (1999). Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation 100: 468-474.
40. Rosengart, T. K., et al. (1999). Six-month assessment of a phase I trial of angiogenic gene therapy for the treatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA. Ann. Surg. 230: 466-470.
41. Harvey, B. G., Worgall, S., Ely, S., Leopold, P. L., and Crystal, R. G. (1999). Cellular immune responses of healthy individuals to intradermal administration of an E1-E3-adenovirus gene transfer vector. Hum. Gene Ther. 10: 2823-2837.
42. Harvey, B. G., et al. (1999). Airway epithelial CFTR mRNA expression in cystic fibrosis patients after repetitive administration of a recombinant adenovirus. J. Clin. Invest. 104: 1245-1255.
43. Harvey, B. G., et al. (1999). Variability of human systemic humoral immune responses to adenovirus gene transfer vectors administered to different organs. J. Virol. 73: 6729-6742.
44. Harvey, B. G., Hackett, N. R., Ely, S., and Crystal, R. G. (2001). Host responses and persistence of vector genome following intrabronchial administration of an E1(-)E3(-) adenovirus gene transfer vector to normal individuals. Mol. Ther. 3: 206-215, doi.10.1006/mthe.2001.0244.
45. Harvey, B. G., et al. (2001). Safety of local delivery of low and intermediate dose adenovirus gene transfer vectors to individuals with a spectrum of comorbid conditions. Hum. Gene Ther. 13: 15-63.
46. Crystal, R. G., et al. (2001). Analysis of risk factors for local delivery of low and intermediate dose adenovirus gene transfer vectors to individuals with a spectrum of comorbid conditions. Hum. Gene Ther. 13: 65-100.
47. Mittereder, N., March, K. L., and Trapnell, B. C. (1996). Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J. Virol. 70: 7498-7509.
48. Rosenfeld, M. A., et al. (1992). In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium. Cell 68: 143-155.